Drug Trial Radar · NCT03945812
Platelet-Rich Plasma vs. Granulocyte Colony-Stimulating Factor vs. Placebo and Outcomes in Frozen Embryo Transfer
Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
665
Actual
Start
Jun 1, 2019
Primary completion
Mar 31, 2022
Study completion Mar 8, 2023
Sponsor
- Lead sponsor
- Wael Elbanna ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Research Centre, Egypt
- First posted
- May 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the impact of using Platelet-Rich Plasma (PRP) vs. Granulocyte Colony-Stimulating Factor (GCSF) vs. placebo on the outcomes of frozen embryo transfer (FET) in terms of clinical pregnancy rates. It will also assess their effect on chemical pregnancy rate, implantation rate, delivery outcomes, and endometrial parameters. The main questions it aims to answer are: Do the clinical pregnancy rates differ upon using PRP vs. GCSF vs. placebo during FET? What are the effects of PRP vs. GCSF vs. placebo during FET on chemical pregnancy rate, implantation rate, delivery outcomes, and endometrial parameters? Researchers will compare the effect of administration of PRP vs. GCSF vs. placebo during FET on pregnancy outcomes. Participants will be randomized to receive the study intervention seven days before embryo transfer: 1.0 ml of either PRP (prepared in-house), GCSF (Filgrastim, 300 mcg/1.0 mL), or 0.9% saline (placebo). The intervention will be administered by slow infusion into the uterine cavity with an intrauterine insemination catheter.
Conditions
- Infertility
- Frozen Embryo Transfer (FET)
Interventions
Granulocyte Colony Stimulating FactorDrug
Filgrastim, Amgen, California, USA 300 mg/1.0 mL
Platelet Rich Plasma ArmOther
Platelet Rich Plasma Arm
SalineOther
Saline 9%
Primary outcomes
What the sponsor says the trial is designed to measure.
- The clinical pregnancy rateTime frame: 6 to 8 weeks of embryo transfer
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hayat center
Maadi, Cairo Governorate, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.